Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
The closing price of Cardlytics Inc (NASDAQ: CDLX) was $2.76 for the day, up 92.66% from the previous closing price of $1.43. In other words, the price has increased by $92.66 from its previous closing price. On the day, 122.76 million shares were traded. CDLX stock price reached its highest trading level at $3.16 during the session, while it also had its lowest trading level at $1.4204.
Ratios:
Our analysis of CDLX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.16 and its Current Ratio is at 1.16. In the meantime, Its Debt-to-Equity ratio is 3.75 whereas as Long-Term Debt/Eq ratio is at 2.95.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The Stock’s future direction. In the most recent recommendation for this company, Evercore ISI on October 11, 2024, initiated with a In-line rating and assigned. The Stock a target price of $4.
On August 16, 2024, Northland Capital Downgraded its rating to Market Perform which previously was Outperform but kept the price unchanged to $5. BofA Securities Downgraded its Neutral to Underperform on August 15, 2024, whereas the target price for. The Stock was revised from $4 to $3.50.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 18 ’25 when SOSIN CLIFFORD sold 200,000 shares for $1.14 per share. The transaction valued at 228,220 led to the insider holds 5,399,023 shares of the business.
SOSIN CLIFFORD sold 200,000 shares of CDLX for $224,540 on Aug 19 ’25. The 10% Owner now owns 5,199,023 shares after completing the transaction at $1.12 per share. On Aug 18 ’25, another insider, Gupta Amit, who serves as the Chief Executive Officer of the company, sold 68,260 shares for $1.12 each. As a result, the insider received 76,792 and left with 560,444 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CDLX now has a Market Capitalization of 146667664 and an Enterprise Value of 320334656. For. The Stock, the TTM Price-to-Sale (P/S) ratio is 0.55 while its Price-to-Book (P/B) ratio in mrq is 2.49. Its current Enterprise Value per Revenue stands at 1.203 whereas that against EBITDA is -10.167.
Stock Price History:
The Beta on a monthly basis for CDLX is 1.24, which has changed by -0.24931878 over the last 52 weeks, in comparison to a change of 0.16298151 over the same period for the S&P500. Over the past 52 weeks, CDLX has reached a high of $5.24, while it has fallen to a 52-week low of $0.85. The 50-Day Moving Average of. The Stock is 80.55%, while the 200-Day Moving Average is calculated to be 22.58%.
Shares Statistics:
CDLX traded an average of 1.66M shares per day over the past three months and 14153900 shares per day over the past ten days. A total of 52.99M shares are outstanding, with a floating share count of 50.33M. Insiders hold about 5.46% of the company’s shares, while institutions hold 45.39% stake in the company. Shares short for CDLX as of 1756425600 were 7597587 with a Short Ratio of 4.58, compared to 1753920000 on 6438256. Therefore, it implies a Short% of Shares Outstanding of 7597587 and a Short% of Float of 16.63.
Earnings Estimates
The market rating of Cardlytics Inc (CDLX) is currently shaped by the ongoing analysis conducted by 3.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.1, with high estimates of -$0.04 and low estimates of -$0.15.
Analysts are recommending an EPS of between -$0.46 and -$0.8 for the fiscal current year, implying an average EPS of -$0.62. EPS for the following year is -$0.45, with 3.0 analysts recommending between -$0.3 and -$0.61.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 4 analysts. It ranges from a high estimate of $63.8M to a low estimate of $53.07M. As of the current estimate, Cardlytics Inc’s year-ago sales were $67.06MFor the next quarter, 4 analysts are estimating revenue of $58.85M. There is a high estimate of $62.8M for the next quarter, whereas the lowest estimate is $55.81M.
A total of 4 analysts have provided revenue estimates for CDLX’s current fiscal year. The highest revenue estimate was $243.4M, while the lowest revenue estimate was $234.03M, resulting in an average revenue estimate of $238.54M. In the same quarter a year ago, actual revenue was $278.3MBased on 5 analysts’ estimates, the company’s revenue will be $228.85M in the next fiscal year. The high estimate is $250.1M and the low estimate is $202.24M.
